Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Rajat Bannerji(Rutgers, The State University of New Jersey), Max S. Topp(Universitätsklinikum Würzburg), Robert L. Charnas(Regeneron (United States)), Kevin A. David(Rutgers, The State University of New Jersey), Olulanu H. Aina(University of California, Davis), Gavin Thurston(Regeneron (United States)), Jennifer R. Brown(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Srikanth Ambati(Regeneron (United States)), Sara Hamon, David Sternberg(Daiichi Sankyo (United States)), John N. Allan(Cornell University), Jeffrey A. Barnes(Harvard University), Robin Joyce(Beth Israel Deaconess Medical Center), Anfal Ibrahim(Regeneron (United States)), Lieve Adriaens(Regeneron (United States)), Israel Lowy(Bristol-Myers Squibb (Germany)), Peter Martin(Northwestern University), Melanie Ufkin(Regeneron (United States)), Peter Gasparini(Regeneron (United States)), Raquel P. Deering(Regeneron (United States)), Stephen M. Ansell(Mayo Clinic), Ranjana H. Advani(Stanford Medicine), Johannes Duell(Universitätsklinikum Würzburg), Nathalie Fiaschi(Regeneron (United States)), Julio C. Chávez(Moffitt Cancer Center), George D. Yancopoulos(Regeneron (United States)), Wen Zhang(Regeneron (United States)), Min Zhu(Eye & ENT Hospital of Fudan University), Andrew Murphy(DePaul University), Vladimir Janković(Regeneron (United States)), Jingjin Li(Inner Mongolia Agricultural University), David M. Weinreich(Regeneron (United States)), Susan O’Brien(University of California, Irvine)
Cited by 57
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k